A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521658-40-00

Acronym

EGL-311

Enrollment

Registered

2025-10-01

Start date

2025-10-27

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Germany, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026